More info
|
Assay Range |
156 - 10,000 pg/mL |
|
Sensitivity |
10.0 pg/mL |
|
Size |
96T |
|
Storage |
Store at 2 - 8ºC. Keep reconstituted standard and detection Ab at -20 ºC |
|
Assay Principle |
Sandwich ELISA |
|
Sample volume |
100 µL final volume, dilution factor varies on samples. |
|
Detection Method |
Chromogenic |
Kit Components
1. Recombinant Human PAI-1 standard: 2 vials.
2. One 96-well plate precoated with anti- Human PAI-1 Ab
3. Sample diluent buffer: 12 mL - 1
4. Detection antibody: 130 µL, dilution 1:100.
5. Streptavidin-HRP: 130 µL, dilution 1:100
6. Antibody diluent buffer: 12 mL x1
7. Streptavidin-HRP diluent buffer: 12 mL x1
8. TMB developing agent: 10 mL x1
9. Stop solution: 10 mL x1.
10. Washing solution (20x): 25 mL x1.
Background
Plasminogen Activator Inhibitor-1 (PAI-1), also known as Serpin E1, Endothelial plasminogen activator inhibitor, is a member of the serpin superfamily of serine protease inhibitors. PAI-1 has been detected in plasma, platelets, endothelial cells, hepatoma and fibrosarcoma. It is reported that free Serpin E1 is relatively unstable in its active form and readily converts into a latent, inactive form by spontaneous insertion of its reactive center loop (RCL) into the β-sheet core of the protein. Serpin E1 exhibits its primary functions in inhibiting urokinase-type and tissue-type plasminogen activators (uPA and tPA), which convert plasminogen to plasmin. It is shown that the active form of Serpin E1 binds tightly with uPA and tPA in a 1:1 ratio. After the formation of an initial docking complex, the proteases cleave the RCL of Serpin E1 to form a stable, covalent complex, resulting in the inactivation of the targeted protease. The PA-plasmin system participates in multiple physiological and pathological processes such as fibrinolysis, fibrosis, angiogenesis, wound healing, and tumor cell invasion and metastasis. Clinically, Serpin E1 has been linked to many diseases such as metabolic syndrome, asthma, major depressive disorder (MDD), and aging-related pathologies. High levels of uPA and Serpin E1 correlate with poor prognosis in patients with breast cancer, and uPA and Serpin E1 are among the most reliable biomarkers. The absence of Serpin E1 in plasma causes abnormal bleeding, and high plasma levels of Serpin E1 are associated with inherited thrombophilia.